A study suggested that kaempferol could be a potential therapeutic anticancer agent against pancreatic cancer in combination with erlotinib through the inhibition of the PI3K/Akt signaling pathway and epidermal growth factor receptor (EGFR) (Zhang et al., 2021b). The gene discussed is EGFR; the disease is familial pancreatic carcinoma.